Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: Calibration to international units, enhanced genotype reactivity, and performance characteristics

Journal of Clinical Microbiology

Volumn 38, Issue 11, 2000, Pages 4171-4179

  Lee, S C ^a   Antony, A ^a   Lee, N ^a   Leibow, J ^a   Yang, J Q ^a   Soviero, S ^a   Gutekunst, K ^a   Rosenstraus, M ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ARTICLE; CALIBRATION; DEVICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENOTYPE; HEPATITIS C VIRUS; HUMAN; INTERNATIONAL STANDARD UNIT; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; QUALITATIVE DIAGNOSIS; QUANTITATIVE ASSAY; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS DETECTION; VIRUS DIAGNOSIS; VIRUS GENOME; VIRUS LOAD;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0034461502     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.38.11.4171-4179.2000     Document Type: Article

References (38)

1. Hepatitis C and liver transplantation
2. Regression analysis
3. Treatment of chronic hepatitis C with interferon-alpha by monitoring the response according to viraemia
4. Predictors of patient and graft survival following liver transplantation for hepatitis C
5. Factors predictive of a beneficial response to therapy of hepatitis C
6. A French consensus conference on hepatitis C: Screening and treatment
7. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant
8. Consensus statement
9. Clinical applications of hepatitis C virus genotyping and quantitation
10. Antibodies to hepatitis C virus envelope proteins correlate with hepatitis C viraemia after liver transplantation
11. Quantitative measurement of HCV RNA in the serum: A comparison of three assays based on different principles
12. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
13. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C
14. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C
15. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C
16. Quality assessment of hepatitis C virus nucleic acid amplification methods
17. Detection of Chlamydia trachomatis in endocervical specimens by polymerase chain reaction
18. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: A 4-year follow-up of 211 patients
19. Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays
20. Management of hepatitis C
21. Comparative study of a modified competitive RT-PCR and Amplicor HCV monitor assays for quantitation of hepatitis C virus RNA in serum
22. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?
23. Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays
24. A comparison of reverse transcription-polymerase chain reaction and branched-chain DNA assays for hepatitis C virus RNA in patients receiving interferon treatment
25. Is an "à la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
26. Comparison of 3 quantitative HCV RNA assays - Accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C
27. An internal control for routine diagnostic PCR: Design, properties and effect on clinical performance
28. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C
29. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group
30. Hepatitis C virus infections in dialysis centers in The Netherlands: A national survey by serological and molecular methods
31. Quantitative assays for hepatitis C virus in serum as predictors of the long-term response to interferon
32. Serum levels of hepatitis C virus RNA predict non-response to interferon therapy: Comparison of two commercial assays
33. Long-term retreatment in chronic hepatitis C patients who were non-responders to an initial course of interferon-alpha 2b
34. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level
35. Monitoring of serum levels of HCV RNA in early phase of IFN therapy; as a predictive marker of subsequent response
36. Dynamics of hepatitis C viremia following interferon-alpha administration
37. Detection of hepatitis C virus RNA by a combined reverse-transcriptase-polymerase chain reaction assay
38. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa